The Life Sciences and M&A teams advised Ironshore Therapeutics in its definitive agreement to be acquired by Collegium Pharmaceutical (Nasdaq: COLL) for $525 million in cash with the potential for an additional $25 million commercial milestone payment.
Ironshore is a privately held, pharmaceutical company that markets and distributes Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant prescription medicine for the treatment of attention deficit hyperactivity disorder (ADHD) in people six years of age and older and the only stimulant medication that is dosed in the evening.
Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts.
The Goodwin team was led by Stuart Cable, Rob Masella, Robert Dzialo, Tevia Pollard, Samuel Beavers and Connor McMillan.
For additional details on the agreement, please read Collegium’s press release.